Progress in immune prevention of respiratory syncytial virus infection in children / 中华实用儿科临床杂志

ABSTRACT

Respiratory syncytial virus (RSV) is the most important viral pathogen causing acute lower respiratory tract infections (ALRTI) in children under 5 years worldwide.RSV is also the primary viral factor leading to ALRTI hospitalization in infants under 1 year.Children are generally susceptible to RSV, and 90% of infants have been infected with RSV before 2 years, which seriously endangers children′s health.Since the discovery of RSV in 1950s, a large number of experiments and explorations on RSV vaccine have been conducted at home and abroad.Nevertheless, there is still no approved RSV vaccine.A breakthrough progress has been made on biological products for the prevention of RSV infection (maternal antibody vaccine, prophylactic monoclonal antibody, etc.), and some of them have entered phase 3 clinical trials.Therefore, it is expected to have effective interventions for preventing RSV infection via passive immune in the next 5-10 years.The Strategic Advisory Group of Experts on Immunization of the World Health Organization reviewed the development of two passive immune agents (maternal antibody vaccine and monoclonal antibody for prevention) in April 2016 to guide the follow-up research.This study systematically reviews the history of passive immunization for the prevention of infectious diseases and the progress in RSV preventive immunization, and summarizes the evidence-based evidence of passive immunity used to prevent RSV infection-related diseases.